ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on November 15, 2017. The filing serves to announce the company's financial results for the quarter ended September 30, 2017. The registrant is identified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative financial analysis.
Guidance, Outlook, and Risks
The filing does not include specific management commentary, forward-looking guidance, risk factors, or contingencies within the main body of the report. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 15, 2017) for actual financial figures for the quarter ended September 30, 2017.
- Verify the company's status as an emerging growth company and any associated accounting standard elections.
- Confirm that the financial data in the press release is not legally incorporated by reference into this specific 8-K filing.
- Check subsequent filings for any updates to the financial results announced in this report.